Abstract
The synthesis of Δ13,(17)-androgens and the structurally related 13,17-epoxides is described. The synthetic route involves cleavage of 17-ketosteroids by an abnormal Beckmann rearrangement, modification of the D-ring cleavage product to obtained an intermediate tricyclic diene and ring closing metathesis of the diene to the Δ13,(17)-androgen. (3α,5α)-Androst-13(17)-en-3-ol and the derivative 13α,17α- and 13β,17β- epoxides were prepared by this route.
Keywords: olefin metathesis, 18-nor-Δ13(17)-steroids, 18-nor-13, 17-epoxysteroids, abnormal Beckmann rearrangement, neurosteroids
The modification of 3α-hydroxysteroids has attracted considerable attention from medicinal and synthetic organic chemists because many compounds in both the androgen and pregnane series are potent modulators of ion channels in the central nervous system of animals.1–5 For example, spiroepoxide 1 (Figure 1) potently enhances the actions of γ-aminobutyric acid (GABA) at type-A GABA (GABAA) receptors and is a general anesthetic in mice.6 However, neither the 16α,17α- nor the 16β,17β-epoxides 2a and 2b, respectively, are as potent modulators of GABAA receptors as spiroepoxide 1.6
Figure 1.

Structures of known (1,2a,2b) neurosteroid modulators of GABAA receptors and the previously unknown modulators (3a,3b) prepared herein.
The actions of the 13α,17α- and 13β,17β-epoxides (3a and 3b) have not been described and, to our knowledge, synthetic routes to 13,17-epoxysteroids are not reported in the literature. To evaluate GABAA receptor actions of these compounds, a synthetic route for their preparation that proceeds through the intermediate Δ13(17)-steroid was developed. The retrosynthetic analysis shown in Scheme 1 utilizes alkene-nitrile 6, obtained from an abnormal Beckmann rearrangement of the oxime of the corresponding 17-ketosteroid, as a precursor for the diene intermediate 5. Ring closure via a ring closing metathesis reaction gives regiospecifically the Δ13(17)-steroid 4, and peracid oxidation of the double bond yields the desired epoxides 3a and 3b.
Scheme 1.

Retrosynthetic analysis for the synthesis of epoxides 3a and 3b.
Thus, the commercially available (3β,5α)-3-hydroxyandrostan-17-one was converted into (3α,5α)-3-(benzoyloxy)androstan-17-one (9, 92% yield) by a Misunobu reaction (Scheme 2).7 Using a standard method, oxime 10 was obtained in 98% yield by treating steroid 9 with H2NOH·HCl and NaOAc. The required alkene-nitrile 6 was conveniently synthesized from oxime 10 in 83% yield using a recently reported method (TFA, CH(OMe)3, THF) that minimizes production of the lactam product of the Beckmann rearrangement.8 Due to the presence of TFA employed in this method, neutralization with 10% Na2CO3 during workup to avoid isomerization of the exocyclic double bond to the 12,13 and 13,14 positions in the secosteroid C-ring is crucial. Treatment of carbonitrile 6 with DIBALH at −78 °C yielded carboxaldehyde 7 in 85% yield.9 A Wittig reaction employing Ph3P+MeBr−/KOBut in dry THF in the usual manner provided diene 5 in 70% yield.10 Ring closure of diene 5 was carried out using a second generation Grubbs’ catalyst.11,12 The Δ13(17)-steroid 4 was obtained in nearly quantitative yield (98%) under mild conditions and with a short reaction time.13 Epoxidation of steroid 4 in dry benzene using mCPBA at room temperature gave a mixture of 13,17-epoxides 3a and 3b which was easily purified by chromatography to yield the less polar 13β,17β-epoxide (3b) and the more polar 13α,17α-epoxide (3a) (4.8:1, 87% in total yield)14,15. The overall yield for the synthesis of the epoxides was 38%.
Scheme 2.

Reagents and conditions: (a) BzOH, Ph3P, DEAD, THF, room temperature, 12 h, 92%; (b) H2NOH·HCl, NaOAc, EtOH, reflux, 12 h, 98%; (c) TFA, CH(OMe)3, THF, N2, 60 °C, 2 h, 83%; (d) DIBALH, N2, CH2Cl2, −78°C, 1 h, 85%; (e) Ph3P+MeBr−, KOBut, THF, room temperature, 60 min, 70%; (f) Grubbs' catalyst 2nd generation, CH2Cl2, N2, 45°C, 1 h, 98%; g. mCPBA, benzene, room temperature, 30 min, 87% (3a, 72%; 3b,15%). Total yield of the synthetic route is 38%.
The stereochemistry for the 13,17-epoxide products was established by single crystal X-ray diffraction analysis of steroid 3b (Figure 2).16 Preliminary biological evaluation of epoxide 3b indicates that the actions of this epoxide at GABAA receptors are weak. As expected, based on previous structure–activity studies of epoxide 2a,6 epoxide 3a has little, if any, effect on GABAA receptor function. Full pharmacological details will be included in a larger study that includes biological data for additional analogues and will be reported elsewhere.
Figure 2.

Crystal structure shown with 50% thermal ellipsoids of one of two unique forms of epoxide 3b.16
In summary, a general and practical method for the preparation of 18-nor-Δ13(17)-steroids has been developed. The sequence features the use of an abnormal Beckmann rearrangement/ring closing metathesis reaction sequence to obtain an 18-nor-Δ13(17)-steroid. Isomeric 18-nor-Δ12-steroids and 18-nor-Δ13-steroids are not formed. The synthetic method was used to extend structure–activity studies of neurosteroid modulators of GABAA receptors.
Supplementary Material
Acknowledgments
This work was supported by NIH grant GM47969. Instrumentation for crystallographic studies was made possible by NSF grant CHE-0420497.
Footnotes
Supplementary data
Supplementary data associated with this article includes procedures for the preparation of compounds 3a,3b,4,5,6,7,9,10 and can be found in the online version. 7
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errorsmaybe discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References and notes
- 1.Phillips GH. J Steroid Biochem. 1975;6:607–613. doi: 10.1016/0022-4731(75)90041-2. [DOI] [PubMed] [Google Scholar]
- 2.Hamilton NM. Curr Top Med Chem. 2002;2:897–902. doi: 10.2174/1568026023393570. [DOI] [PubMed] [Google Scholar]
- 3.Eisenman LN, He Y, Covey DF, Zorumski CF, Mennerick S. Potentiation and Inhibition of GABAA Receptor Function by Neuroactive Steroids. In: Smith SS, editor. Neurosteroid Effects in the Central Nervous System: the Role of the GABAA Receptor. CRC Press; Boca Raton: 2004. pp. 95–117. [Google Scholar]
- 4.Belelli D, Lambert JJ. Nature Rev Neurosci. 2005:565–575. doi: 10.1038/nrn1703. [DOI] [PubMed] [Google Scholar]
- 5.Todorovic SM, Covey DF, Zorumski CF, Jevtovic-Todorovic V. Curr Med Chem – Central Nervous System Agents. 2005;5:157–164. [Google Scholar]
- 6.Anderson A, Boyd AC, Clark JK, Fielding L, Gemmell DK, Hamilton NM, Maidment MS, May V, McGuire R, McPhail P, Sansbury FH, Sundaram H, Taylor R. J Med Chem. 2000;43:4118–4125. doi: 10.1021/jm000977e. [DOI] [PubMed] [Google Scholar]
- 7.Experimental procedures are available online as supplementary data.
- 8.Wang C, Jiang X, Shi J, Lu J, Hu Y, Hu H. J Org Chem. 2003;68:1997–1999. doi: 10.1021/jo034142y. [DOI] [PubMed] [Google Scholar]
- 9.Data for 7: oil; [α]20D = −24.58 (c 0.86, CHCl3); IR 3401, 3080, 2718, 1722, 1643 cm−1; 1H NMR δ 9.71 (t, J = 1.2 Hz, 1H), 4.67 (s, 1H), 4.41 (s, 1H), 3.97 (m, 1H), 0.63 (s, 3H); 13C NMR δ 202.74, 150.60, 104.69, 66.06, 53.17, 47.63, 42.04, 41.92, 38.25, 36.82, 36.18, 35.47, 31.95, 31.51, 28.72, 28.25, 27.14, 19.26, 10.90. Anal. Calcd for C19H30O2: C, 78.57; H, 10.41. Found: C, 78.70; H, 10.24.
- 10.Data for 5: oil; [α]20D −34.52 (c 0.17, CHCl3); IR 3350, 3078, 1641, 1445, 1005 cm−1; 1H NMR δ 5.82 (m, 1H), 5.02 (m, 2H), 4.72 (s, 1H), 4.55 (s, 1H), 4.03 (m, 1H), 0.70 (s, 3H); 13C NMR δ 151.35, 139.34, 113.82, 104.60, 66.36, 53.43, 47.87, 41.89, 38.46, 37.08, 36.32, 35.64, 32.07, 31.72, 30.61, 28.88, 28.47, 27.26, 26.68, 11.00. Anal. Calcd for C20H32O: C, 83.27; H, 11.18. Found: C, 83.14; H, 11.20.
- 11.Chatterjee AK, Grubbs RH. Org Lett. 1999;1:1751–1753. doi: 10.1021/ol991023p. [DOI] [PubMed] [Google Scholar]
- 12.Scholl M, Ding S, Lee CW, Grubbs RH. Org Lett. 1999;1:953–956. doi: 10.1021/ol990909q. [DOI] [PubMed] [Google Scholar]
- 13.Data for 4: white solid; mp 118–120 °C (EtOAc-hexanes), [α]20D −18.9 (c 0.50, CHCl3); IR 3435, 1635, 1444, 1014 cm−1; 1H NMR δ 5.21 (s, 1H), 4.04 ( m, 1H), 0.71 (s, 3H); 13C NMR δ 146.04, 119.95, 66.67, 52.77, 52.44, 45.67, 38.86, 36.40, 36.07, 32.61, 32.47, 31.50, 29.73, 29.14, 28.65, 28.52, 25.87, 11.33. Anal. Calcd for C18H28O: C, 83.02; H, 10.84. Found: C, 83.07; 10.79.
- 14.Data for 3b: colorless crystals; mp 170–172 °C (from EtOAc/hexanes); [α]20D -17.4 (c 0.34, CHCl3); IR 3421, 3335, 1456, 1434, 896 cm−1; 1H NMR δ 4.05 (m, 1H), 3.41 (s, 1H), 0.78 (s, 3H); 13C NMR δ 68.10, 66.29, 62.54, 52.69, 46.75, 39.47, 38.73, 36.19, 35.78, 32.25, 32.00, 28.89, 28.72, 28.18, 27.29, 23.56, 22.85, 11.14. Anal. Calcd for C18H28O2: C, 78.21; H, 10.21. Found: C, 77.98; H, 10.12.
- 15.Data for 3a: white solid; mp 144–146 °C (from EtOAc/hexanes); [α]20D −45.7 (c 0.54, CHCl3); IR 3434, 1445, 1432, 731 cm−1; 1H NMR δ 4.06 (m, 1H), 3.24 (s, 1H), 0.72 (s, 3H); 13C NMR δ 68.85, 66.67, 63.72, 51.91, 46.92, 39.33, 38.86, 36.52, 36.00, 32.86, 32.41, 29.22, 28.99, 28.63, 26.64, 24.48, 23.54, 11.31. Anal. Calcd for C18H28O2: C, 78.21; H, 10.21. Found: C, 77.94; H, 10.00.
- 16.Crystallographic data (excluding structure factors) for the structure in this paper has been deposited with the Cambridge Crystallographic Data Centre as supplementary publication numbers CCDC 612073. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44(0)-1223-330633 or email: deposit@ccdc.cam.ac.uk].
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
